Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of a Novel Dual Angiotensin and Endothelin Receptor Antagonist (PS433540) in Subjects With Stage I and II Hypertension.

Trial Profile

Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of a Novel Dual Angiotensin and Endothelin Receptor Antagonist (PS433540) in Subjects With Stage I and II Hypertension.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2011

At a glance

  • Drugs Sparsentan (Primary)
  • Indications Hypertension
  • Focus Therapeutic Use
  • Sponsors Pharmacopeia
  • Most Recent Events

    • 18 Apr 2009 Actual patient number (280) added as reported by ClinicalTrials.gov.
    • 15 Apr 2008 Interim results will be reported as a late-breaking abstract at ASH 2008.
    • 01 Apr 2008 The expected completion date for this trial is now 1 May 2008, as reported by clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top